DC_AC50

DC_AC50 is a first-in-class small molecule inhibitor of the copper chaperones Antioxidant-1 (ATOX1) and Copper Chaperone for Superoxide Dismutase (CCS). By binding to these chaperones, DC_AC50 disrupts intracellular copper trafficking, which is essential for the function of various enzymes and the sequestration of platinum-based chemotherapeutics. In oncology, DC_AC50 has demonstrated the ability to sensitize human and canine osteosarcoma cells to carboplatin and cisplatin by increasing intracellular platinum accumulation and inducing reactive oxygen species (ROS)-mediated immunogenic cell death. Beyond cancer, it has been investigated for the treatment of aortic dissection, where it reduces extracellular matrix degradation and vascular smooth muscle cell apoptosis by inhibiting ATOX1-mediated copper signaling. It is frequently studied in the context of advanced delivery systems, such as nanoparticles and stimuli-responsive hydrogels, to enhance therapeutic efficacy and reduce systemic toxicity.